| Inducible apoptosis as a safety switch for adoptive cell therapy A Di Stasi, SK Tey, G Dotti, Y Fujita, A Kennedy-Nasser, C Martinez, ... New England Journal of Medicine 365 (18), 1673-1683, 2011 | 1585 | 2011 |
| CD28 costimulation improves expansion and persistence of chimeric antigen receptor–modified T cells in lymphoma patients B Savoldo, CA Ramos, E Liu, MP Mims, MJ Keating, G Carrum, ... The Journal of clinical investigation 121 (5), 1822-1826, 2011 | 1222 | 2011 |
| Human epidermal growth factor receptor 2 (HER2)–specific chimeric antigen receptor–modified T cells for the immunotherapy of HER2-positive sarcoma N Ahmed, VS Brawley, M Hegde, C Robertson, A Ghazi, C Gerken, E Liu, ... Journal of clinical oncology 33 (15), 1688, 2015 | 1010 | 2015 |
| HER2-specific chimeric antigen receptor–modified virus-specific T cells for progressive glioblastoma: a phase 1 dose-escalation trial N Ahmed, V Brawley, M Hegde, K Bielamowicz, M Kalra, D Landi, ... JAMA oncology 3 (8), 1094-1101, 2017 | 702 | 2017 |
| Infusion of donor-derived CD19-redirected virus-specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: a phase 1 study CRY Cruz, KP Micklethwaite, B Savoldo, CA Ramos, S Lam, S Ku, ... Blood, The Journal of the American Society of Hematology 122 (17), 2965-2973, 2013 | 586 | 2013 |
| Multicenter study of banked third-party virus-specific T cells to treat severe viral infections after hematopoietic stem cell transplantation AM Leen, CM Bollard, AM Mendizabal, EJ Shpall, P Szabolcs, JH Antin, ... Blood, The Journal of the American Society of Hematology 121 (26), 5113-5123, 2013 | 583 | 2013 |
| CAR T cells administered in combination with lymphodepletion and PD-1 inhibition to patients with neuroblastoma A Heczey, CU Louis, B Savoldo, O Dakhova, A Durett, B Grilley, H Liu, ... Molecular therapy 25 (9), 2214-2224, 2017 | 454 | 2017 |
| Off-the-shelf virus-specific T cells to treat BK virus, human herpesvirus 6, cytomegalovirus, Epstein-Barr virus, and adenovirus infections after allogeneic hematopoietic stem … I Tzannou, A Papadopoulou, S Naik, K Leung, CA Martinez, CA Ramos, ... Journal of Clinical Oncology 35 (31), 3547, 2017 | 421 | 2017 |
| Clinical and immunological responses after CD30-specific chimeric antigen receptor–redirected lymphocytes CA Ramos, B Ballard, H Zhang, O Dakhova, AP Gee, Z Mei, M Bilgi, ... The Journal of clinical investigation 127 (9), 3462-3471, 2017 | 371 | 2017 |
| Anti-CD30 CAR-T cell therapy in relapsed and refractory Hodgkin lymphoma CA Ramos, NS Grover, AW Beaven, PD Lulla, MF Wu, A Ivanova, T Wang, ... Journal of clinical oncology 38 (32), 3794, 2020 | 288 | 2020 |
| Clinical responses with T lymphocytes targeting malignancy-associated κ light chains CA Ramos, B Savoldo, V Torrano, B Ballard, H Zhang, O Dakhova, E Liu, ... The Journal of clinical investigation 126 (7), 2588-2596, 2016 | 288 | 2016 |
| In vivo fate and activity of second-versus third-generation CD19-specific CAR-T cells in B cell non-Hodgkin’s lymphomas CA Ramos, R Rouce, CS Robertson, A Reyna, N Narala, G Vyas, B Mehta, ... Molecular Therapy 26 (12), 2727-2737, 2018 | 235 | 2018 |
| Inducible caspase-9 suicide gene controls adverse effects from alloreplete T cells after haploidentical stem cell transplantation X Zhou, G Dotti, RA Krance, CA Martinez, S Naik, RT Kamble, AG Durett, ... Blood, The Journal of the American Society of Hematology 125 (26), 4103-4113, 2015 | 233 | 2015 |
| Long-term outcome after haploidentical stem cell transplant and infusion of T cells expressing the inducible caspase 9 safety transgene X Zhou, A Di Stasi, SK Tey, RA Krance, C Martinez, KS Leung, AG Durett, ... Blood, The Journal of the American Society of Hematology 123 (25), 3895-3905, 2014 | 186 | 2014 |
| Local and systemic effects of an allogeneic tumor cell vaccine combining transgenic human lymphotactin with interleukin-2 in patients with advanced or refractory neuroblastoma RF Rousseau, AE Haight, C Hirschmann-Jax, ES Yvon, DR Rill, Z Mei, ... Blood, The Journal of the American Society of Hematology 101 (5), 1718-1726, 2003 | 136 | 2003 |
| Tumor response and endogenous immune reactivity after administration of HER2 CAR T cells in a child with metastatic rhabdomyosarcoma M Hegde, SK Joseph, F Pashankar, C DeRenzo, K Sanber, S Navai, ... Nature communications 11 (1), 3549, 2020 | 117 | 2020 |
| Immunotherapy of high-risk acute leukemia with a recipient (autologous) vaccine expressing transgenic human CD40L and IL-2 after chemotherapy and allogeneic stem cell … RF Rousseau, E Biagi, A Dutour, ES Yvon, MP Brown, T Lin, Z Mei, ... Blood 107 (4), 1332-1341, 2006 | 95 | 2006 |
| Responses to human CD40 ligand/human interleukin-2 autologous cell vaccine in patients with B-cell chronic lymphocytic leukemia E Biagi, R Rousseau, E Yvon, M Schwartz, G Dotti, A Foster, ... Clinical cancer research 11 (19), 6916-6923, 2005 | 93 | 2005 |
| EBV/LMP-specific T cells maintain remissions of T-and B-cell EBV lymphomas after allogeneic bone marrow transplantation LP McLaughlin, R Rouce, S Gottschalk, V Torrano, G Carrum, MF Wu, ... Blood, The Journal of the American Society of Hematology 132 (22), 2351-2361, 2018 | 64 | 2018 |
| Safety and anti-tumor activity of CD5 CAR T-cells in patients with relapsed/refractory T-cell malignancies LQC Hill, RH Rouce, TS Smith, L Yang, M Srinivasan, H Zhang, ... Blood 134, 199, 2019 | 61 | 2019 |
